NeuroRPM, a digital health company focused on Parkinson’s disease monitoring, today announced that its FDA-cleared wearable platform will be used for digital biomarker monitoring in Annovis Bio’s ANVS ...

Parkinson's disease is the fastest growing neurological disorder, with more than 10 million cases worldwide. Up to 150,000 ...

From standard medications to advanced drug delivery, surgery, and regenerative approaches, Parkinson's treatment options in ...

A boxing class in Baltimore is helping people living with Parkinson's disease make connections in more ways than one.

Annovis Bio, Inc. (NYSE: ANVS) ('Annovis” or the 'Company”), a Phase 3 clinical-stage biotechnology company developing the ...

Parkinson’s disease is the fastest growing neurological disorder, with over 10 million cases worldwide. Up to 150,000 Australians currently live with the disease and 50 new cases are diagnosed each ...

Aspen Neuroscience’s stem cell therapy improved Parkinson’s disease symptoms for all eight treated patients after one year, with the San Diego biotech now planning for a pivotal phase 3 trial later ...

New research based on nearly 11,000 people shows Parkinson's can present differently in men and women, with distinct symptom patterns and risk exposures that may influence diagnosis and care.

A three year study reveals how Parkinson's symptoms evolve, highlighting the value of patient reports and wearables in monitoring disease.

A growing body of research into Parkinson’s disease is challenging the assumption that the condition looks the same in every ...

Parkinson’s Cafe@AH allows multidisciplinary teams to monitor patients in a relaxed environment. Read more at straitstimes.com. Read more at straitstimes.com.